ArticleJournal of vascular surgery2026
Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events.
Article in Journal of vascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Perivascular adipokine signaling in abdominal aortic aneurysm: cardiometabolic drivers of vascular remodeling and translational opportunities.Cardiovascular diabetology · 2026Review
- GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.Diabetology & metabolic syndrome · 2026Review
- Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model.Biomedicines · 2026Article
- Thrombo-inflammation as a missing variable in thoracic aortic intervention timing: toward a biology-informed threshold.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveGlucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown to possess cardiovascular protective effects, with preclinical data, suggesting potential benefits in slowing abdominal aortic aneurysm (AAA) growth. However, their effect on AAA in humans remains underexplored. This study evaluates the effects of GLP-1RAs on all-cause mortality, AAA repair, and acute abdominal aortic syndrome in patients with unruptured AAA.
methodsWe used the US collaborative network of the TriNetX platform to identify patients aged ≥18 years with unruptured AAA, based on International Classification of Disease, 10th Revision (ICD-10), codes from January 1, 2015, to March 1, 2020. Patients with prior AAA rupture, dissection, repair, and connective tissue disorders were excluded. The remaining cohort was stratified by type 2 diabetes (T2D) status and divided into two cohorts: patients who had GLP-1RA prescription within 6 months before or any time after their first AAA encounter diagnosis during the study period and non-GLP-1RA users who were never prescribed GLP-1RAs. Propensity score matching (1:1) adjusted for demographics, tobacco use, comorbidities, and medications. Five-year odds ratios (ORs) and Kaplan-Meier survival analyses assessed outcomes.
resultsOf the 1407 patients prescribed GLP-1RAs and 38,994 not prescribed GLP-1RAs with T2D, 1401 patients were matched and analyzed. Similarly, among 336 patient prescribed GLP-1RAs and 129,790 not prescribed non-GLP-1RAs without T2D, 336 matched pairs were analyzed. Patient prescribed GLP-1RAs had significantly lower risks of the composite outcome of mortality, AAA repair, and acute abdominal aortic syndrome in both T2D (OR, 0.56; 95% confidence interval [CI], 0.47-0.66) and non-T2D cohorts (OR, 0.42; 95% CI, 0.28-0.63). Specifically, those prescribed GLP-1RAs had reduced mortality (T2D: OR, 0.54; 95% CI, 0.45-0.65; non-T2D: OR, 0.47; 95% CI, 0.30-0.74) and were less likely to undergo AAA repair (T2D: OR, 0.66; 95% CI, 0.45-0.95; non-T2D: OR, 0.45; 95% CI, 0.21-0.96). Kaplan-Meier analysis also demonstrated the benefits of GLP-1RAs in delaying outcome.
conclusionsGLP-1RA prescriptions were associated with a lower risk of clinically important events in patients with unruptured AAA. These findings suggest potential benefits of GLP-1RAs in AAA management, warranting further research on their effect on aneurysm growth and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.